Interventional cardiologist and researcher. Azienda Sanitaria Locale Torino 4, Cirié, Torino, Italy & Università della Svizzera Italiana, Lugano, Switzerland.
Turin, Piedmont
Joined September 2019
- Tweets230
- Following182
- Followers246
- Likes218
Dr Luigi Biasco retweeted
Upon the occasion of #EuroPCR, the PCRonline Editorial Board, led by Editor-in-Chief @sbrugaletta and the Journal Club team, led by Journal Club Chair @NicolaRyanI1, could meet up in person, exchange ideas and discuss content strategy.
We are so grateful 🙏 to each and every one of you for your commitment and collaboration, 365 days a year.
Your expertise and input - based on the PCR philosophy of "by and for" - make PCRonline.com the trusted source for the interventional cardiovascular community :
@mirvatalasnag , @kiadeb87, @CurioJonathan, @deharo_pierre, @DanieleGiacoppo, @KVM83, @MilasinD18, @ANazmiCalik, @OhnoTuri, @Ortega_Paz, @Sticchi_Alex, Christian Frerker, Flavio Ribichini, @aayshacader @BiascoDr, @PCapranzano, @PamelaGatto, @MartineGilard, @VijayKunadian, @AsherElad, @panosxap, @DFCapodanno @Dr_AshokSeth
Full Editorial Board list 🔗 pcronline.com/About-PCR/Who-…
Journal Club team 🔗 pcronline.com/PCR-Publicatio…
A big thank you also to the many other contributors not listed here who share their knowledge, experience and practice with their peers. #PCRCompanions
Dr Luigi Biasco retweeted
The FDA has approved TAVI for asymptomatic patients with severe aortic stenosis - don't miss this special session at #EuroPCR on "TAVI for asymptomatic aortic stenosis after EARLY TAVI & TAVI and coronary artery disease after NOTION-3"!
Wednesday 21/05 15-16h
🗓️ pcronline.com/Courses/EuroPC…
@DFCapodanno @l_rosseel @BiascoDr @vinesteves @drtpatterson @PatrizioLancel2 @MichaelJoner3
FDA Approves TAVI for Asymptomatic Patients With Severe Aortic Stenosis tctmd.com/news/fda-approves-…
Will there be any updates to this recommendation in the 2025 VHD guidelines?
@ESC_Journals @escardio @PCRonline @FabienPraz
Dr Luigi Biasco retweeted
#EuroPCR 2025 ViTAL® session in progress.
A wonderful opportunity to learn & share, working together towards a common goal:
To provide the best possible educational experience for our attendees, PCR-style 🫶
@NievesGonzalo1 @CuissetDr @nicolasdumonte1
#CardioEd #medicaleducation #keeponlearning #interventionalcardiology
Dr Luigi Biasco retweeted
🔥#ACC25 Late-Breaking Trials 🔥: a sub-analysis of the Early TAVR trial
🔗pcronline.com/News/Whats-new…
@BiascoDr reviews this sub-analysis of the Early TAVR trial that provides new insights about early and delayed aortic valve replacement implant patients
#TAVI #TAVR #interventionalcardiology
Dr Luigi Biasco retweeted
Gearing up for #ACC25 ⌛️ ? So are we!
🔗pcronline.com/News/Whats-new…
Get the #interventionalcardiology perspective from this year's major LBTs provided to you by @mirvatalasnag, @AsherElad , @BiascoDr , @aayshacader, @ANazmiCalik, @CurioJonathan, @kiadeb87, @DanieleGiacoppo, @KVM83 , @OhnoTuri, @Ortega_Paz, @NicolaRyanI1, @Sticchi_Alex and @panosxap
Watch this space! @sbrugaletta
Dr Luigi Biasco retweeted
What I learned today @CRT_meeting :
🎓More #WhyCMR studies are performed in London alone than the entire USA & cost is lower in UK
🎓Health Apps can be by prescription only #DiGA
❓Unanswered Q: How do we select patients suitable for digital follow-up? Will the future overwhelm patients with devices/Apps on par with the poly pharmacy dilemma?
🎓Virtual cockpits allow remote access to tertiary level expertise eg #SehaVirtualHospital @AdelTash
@mmamas1973 @DrPascalMeier @BruiningNico @DrKoltowski
Dr Luigi Biasco retweeted
“Vulnerable or High-Risk Plaque: A JACC Cardiovascular Imaging Position Statement” just published in @JACCJournals
jacc.org/doi/10.1016/j.jcmg.…
#atherosclerosis #vulnerableplaque #highriskplaque #imaging #OCT #IVUS #NIRS #deepOCT #CT #PCCT #MRI #lipid #lipidlowering #PCI #outcome
Dr Luigi Biasco retweeted
🚨 CALL for RESEARCH TOPICS 🚨
from #EAPCI Research Initiatives and Innovation Committee 🧪🔬
🎯 Submit your proposal until 22 February using the form 👉 bit.ly/4gqUBw3
📥 Submissions will be evaluated based on 3 key criteria;
🔑 Innovation
🔑 Feasibility within a two-year term
🔑 Involvement of the #EAPCI network
@GGStefanini @piotr_buszmanMD
Dr Luigi Biasco retweeted
#EuroPCR 2025
🟣Have you submitted your science and cases?
🟣8 awards up for grabs!
🚨Deadline 2359 CET TODAY!
Submit here:
pcronline.com/Courses/EuroPC…
@PCRonline @CuissetDr @NievesGonzalo1 @nicolasdumonte1 @ANazmiCalik @KardiologieHH @kiadeb87 @NicolaRyanI1 @valeriaparadies
For all our #EAPCI members
⏰ Do not miss the opportunity to apply for #EuroPCR 2025 call for
⭐️scientific abstracts
⭐️late breaking clinical trials
⭐️clinical cases
⭐️images
⭐️innovation
⌛️Deadline 👉 12 January - 23:59 (CET)
📮SUBMIT NOW 👉 bit.ly/3BTpawp
@PCRonline @CuissetDr @nicolasdumonte1 @NievesGonzalo1 @MartineGilard @EmanueleBarba13 @sbrugaletta @MilasinD18 @M_Lesiak @valeriaparadies @mirvatalasnag @KardiologieHH @NicolaRyanI1 @Sticchi_Alex @ANazmiCalik @marioiancardio @aleks_gasecka
Dr Luigi Biasco retweeted
Dopo la trasmissione Report (RAI3) del 29 Dicembre 2024 sull'impianto percutaneo della valvola aortica cardiaca (TAVI) sono necessarie importanti precisazioni per i pazienti e i loro familiari. Leggi la notizia completa gise.it/notizie/ordinaria/0/…
Dr Luigi Biasco retweeted
TAVI and FFR-guided PCI vs. SAVR and CABG in aortic stenosis with complex or multivessel coronary artery disease
🔗pcronline.com/PCR-Publicatio…
Read this new #EAPCI/PCR Journal Club review by @NicolaRyanI1
#TAVI #TAVR #CABG #HeartTeam #JournalClub #interventionalcardiology
Dr Luigi Biasco retweeted
#TCT2024 Late-breaking trials
EARLY TAVR is big news at TCT! @BiascoDr provides his take on the results 📊 of this trial, presented by @PhilGenereuxMD in Washington.
Read review here 🔗 pcronline.com/News/Whats-new…
#TAVI #TAVR #cardiotwitter
Dr Luigi Biasco retweeted
Getting ready for #TCT2024 🇺🇸? So are we!
Make sure you get the international perspective thanks to condensed take-home reviews✍️ covering major late-breaking clinical trials 📈📉📊 from @mirvatalasnag @AsherElad @BiascoDr @aayshacader @ANazmiCalik, @DanieleGiacoppo @MilasinD18 @NicolaRyanI1 @Sticchi_Alex and @panosxap!
🔗 pcronline.com/News/Whats-new…
#interventionalcardiology #cardiotwitter #CardioEd #cardiology #LBCT
Dr Luigi Biasco retweeted
Live from the #ESCCongress in London 🇬🇧
MitrAI score: machine learning models to predict mortality at 12, 24, 36 and 48 months in patients with primary and secondary MR treated by #TEER
Read this analysis ✍️ by @CurioJonathan
pcronline.com/News/Whats-new…
#TMVR #AI
Dr Luigi Biasco retweeted
Besides the education & science, #EuroPCR is also the opportunity to catch-up on activities that take place all year long.
Thank you 🙏 to the #EAPCI/PCR Journal Club team, led by @NicolaRyanI1 for all their hard work in reviewing ✍️ major scientific papers for PCR.online.com. View content ➡️pcronline.com/PCR-Publicatio…
Here is the full list of contributors ➡️ pcronline.com/PCR-Publicatio…
On this photo from left-to-right: @ANazmiCalik @Sticchi_Alex @panosxap @aayshacader @NicolaRyanI1 @BiascoDr @DanieleGiacoppo.
Not present on the photo, but very much present as contributors: @mirvatalasnag @AsherElad & @sbrugaletta
Thank you again to @MilasinD18, now #PCRwebinar Medical Director, for his contribution throughout the years. We will miss him, but it's for a good cause 😉
Dr Luigi Biasco retweeted
NOTION-2 did not demonstrate the noninferiority of TAVI compared to surgery for the primary endpoint at 1 year. Due to fewer events than anticipated in the surgery group, the trial lost statistical power, resulting in widened confidence intervals that crossed both the noninferiority boundary and the line of identity.
This is the methodological situation where a noninferiority trial is termed "Inconclusive" because no result can be significantly excluded. We cannot say TAVI is noninferior, we can't say it is inferior, we can't say it is superior. Check mate.
That said, NOTION-2 remains valuable for descriptive purposes and inclusion in meta-analyses. Long-term results with increased event rates will provide additional insights on the comparison of TAVI and SAVR in younger, low-risk patients.
academic.oup.com/eurheartj/a…
Dr Luigi Biasco retweeted
#EuroPCR 2024 Major LBT – LANDMARK
Previous head-to-head comparisons of new THVs with established devices confirmed no class effect of clinical benefits after #TAVI with inferior safety & efficacy for some of them.
Validation of MyVal non-inferiority to the most widely used balloon-expandable and self-expandable platforms is therefore significant.
Dr Luigi Biasco retweeted
#EuroPCR 2024 Major LBTs 🔥LANDMARK
Early outcomes of a randomised non-inferiority trial comparing #TAVI devices.
Results of this trial presented by P.W. Serruys, on Wednesday 15/05 at 08h30. Followed by a methodology insight by @DFCapodanno & impact in practice by @MartyBLeon
Dr Luigi Biasco retweeted
A Torino il congresso internazionale Change in Cardiology 4.0 ansa.it/piemonte/notizie/202…
Dr Luigi Biasco retweeted
#ACC24: #ORBITA-COSMIC
@aayshacader interviews 🎤 @rallamee and @MikeFoley89 about this trial that showed that coronary sinus reducer relieved angina symptoms, but lacked evidence of increased blood flow to the heart.
While beneficial for refractory angina patients, its mechanism remains unclear.
📺pcronline.com/News/Whats-new…
#interventionalcardiology
